Navigation Links
Alfacell Receives NASDAQ Delisting Letter
Date:8/1/2008

SOMERSET, N.J., Aug. 1 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that it received a NASDAQ staff determination letter on July 29, 2008 notifying the Company that its securities will be delisted from The NASDAQ Capital Market. On June 25, 2008, NASDAQ notified the Company that the market value of its listed securities had been below the minimum $35 million required for continued inclusion on The NASDAQ Capital Market under Marketplace Rule 4310(c)(3)(B) for the previous 10 consecutive trading days. In accordance with Marketplace Rule 4310(c)(8)( C), the Company was provided with a grace period of 30 calendar days, or until July 25, 2008, to regain compliance with the minimum market value requirement. The staff determination letter states that the Company has not regained compliance within the given grace period and as a result, unless the Company requests an appeal of the staff determination, trading of the Company's common stock will be suspended at the opening of business on August 7, 2008, and a Form 25-NSE will be filed with the Securities and Exchange Commission, or the SEC, to remove the Company's securities from listing and registration on NASDAQ.

The staff determination letter further states that the Company may appeal the delisting determination to a NASDAQ Listing Qualification Panel, or the Panel, by submitting a hearing request. A hearing request will stay the suspension of the Company's securities and the filing of the Form 25-NSE pending the Panel's decision, if the Hearings Department receives the Company's hearing request on or before 4:00pm Eastern Time on August 5, 2008. The Company intends to timely submit a hearing request and to present its arguments and/or plan of complia
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Alfacell Receives NASDAQ Non-Compliance Notification
2. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
3. Alfacell Announces Retirement of Chief Executive Officer
4. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
5. Alfacell to Host Fiscal Second Quarter 2008 Financial Results Conference Call and Webcast
6. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
7. Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29
8. Alfacell to Host Fiscal Fourth Quarter and Year-End 2007 Financial Results Conference Call and Webcast
9. Alfacell to Present at BIO InvestorForum 2007
10. Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
11. Workforce Alliance Receives U.S. Labor Departments Excellence Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014 Astra Nova Training ... consultancy and pharma training services, and the ... , a non-profit integrating the expertise and investments ... a global system for clinical trials, are pleased ... the expertise of industry professionals through improved and ...
(Date:7/22/2014)... WASHINGTON D.C., June 22, 2014 Even within a phylum ... fly is distinguished among other arthropods for its cruelty -- ... and Central America, the fly is a most predatory sort ... male cricket, deposits a smear of larvae, and leaves its ... inside out. , None of this would be possible ...
(Date:7/22/2014)... mechanical engineering at the University of Texas at Dallas, ... North Texas section of the American Society of Mechanical ... in 158 countries who develop engineering standards and training. ... benefiting the world. , ASME recognized Baughn earlier this ... banquet. Baughn retired as an engineering fellow in 2012 ...
(Date:7/22/2014)... July 22, 2014 CTD Holdings, Inc. ... pharmaceutical, medical device, cosmetics, and other markets, announced today ... a group of qualified private investors led by Novit ... , The transaction involved the signing of a ... shares of Common Stock at a price per share ...
Breaking Biology Technology:Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 2Astra Nova and ACRES Partner on Quality and Access of Training for Research Professionals 3Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4UT Dallas professor receives Engineer of the Year award 2CTD Holdings Closes $1.725 Million Private Placement 2CTD Holdings Closes $1.725 Million Private Placement 3
... Target Underlying Defect in Cystic Fibrosis; CFTR ... ... BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that it ... covering compounds demonstrated to improve cystic,fibrosis transmembrane conductance regulator (CFTR) ...
... -. Actavis Group, the,international generic pharmaceuticals company, ... the U.S. Food & Drug Administration to ... will begin,immediately. Fentanyl Transdermal System is ... in 25, 50, 75 and 100 mcg/hour ...
... HUNTSVILLE, Ala., Aug. 22 DNA2.0,Inc. ... synthetic genes, and,Operon Biotechnologies (http://www.operon.com ), ... formation of a partnership to utilize their,synergistic ... Operon,s oligonucleotide production platform with DNA2.0,s,gene synthesis ...
Cached Biology Technology:BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco 2BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco 3BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco 4Actavis Receives Approval of Fentanyl Transdermal System in the U.S. 2Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership 2
(Date:7/23/2014)... are crucial for providing essential fatty acids and ... feeding. There has been concern that soybean-based emulsions ... due to its composition. Combination lipid emulsions based ... have been developed to address this concern. , ... that concern may be unwarranted, according to a ...
(Date:7/22/2014)... of both still images and video of artistic ... Forty-four still images were chosen from more than ... and alumni representing more than 25 different University ... 50 submissions. , Zach Donnell, a graduate student ... organizers, noted that the exhibit highlights the interplay ...
(Date:7/22/2014)... Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its second quarter ended June 30, 2014. Revenue ... increase of 53% compared to $4.4 million in the same ... the second quarter of 2014 was $1.4 million compared to ... in revenue and operating income was driven by higher sales ...
Breaking Biology News(10 mins):Art of Science 2014 2Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7
... years ago Mark Kay, MD, PhD, published the first ... RNA interference was an effective gene-therapy technique in mice. ... flurry amongst both academic and industry research groups. , ... way, Kay's initial excitement is proving to be on ...
... phones excite the brain cortex adjacent to it, ... other neurological conditions. This finding is published in ... & Sons. The article is also available online ... million people in the world use cell phones ...
... as Ritalin to quell symptoms of attention deficit hyperactivity ... drugs work in the brain. , But new work ... clear up some of the mystery. Writing in the ... primarily target the prefrontal cortex (PFC), a region of ...
Cached Biology News:For Stanford scientists, RNAi gene therapy takes two steps forward, one step back 2Cell phone emissions excite the brain cortex 2Study reveals how ADHD drugs work in brain 2Study reveals how ADHD drugs work in brain 3
... Ligands\n\nReceptor-related research has long been enabled by ... selected to keep pace with new discoveries. ... and services for receptor research and drug ... you do not find exactly what you ...
... pending) was developed using a protein engineering approach ... binding pocket of wild-type DNase I. These changes ... DNA. The result is a versatile enzyme that ... an ability to maintain at least 50% of ...
Rabbit polyclonal to hnRNP-U...
... formation of a phosphodiester bonds between adjacent ... DNA molecules or between oligonucleotides which are ... 45 - 65?. Tfi DNA Ligase is ... than conventional DNA ligases, Thus, Tfi DNA ...
Biology Products: